Terns Pharmaceuticals develops small-molecule therapies for chronic diseases including cancer, metabolic disorders, and liver conditions.
Terns Pharmaceuticals has raised $650.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Terns Pharmaceuticals's investors include Eli Lilly, Vivo Capital, Lilly Asia Ventures, OrbiMed, Decheng Capital.
Terns Pharmaceuticals is headquartered in Foster City, United States.
Terns Pharmaceuticals develops small-molecule therapies for chronic diseases including cancer, metabolic disorders, and liver conditions.
Terns Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Terns Pharmaceuticals — Funding & Investors." VCBacked, December 9, 2025, https://www.vcbacked.co/company/terns-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2025). Terns Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/terns-pharmaceuticals
{{cite web |title=Terns Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/terns-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated